Theravance Biopharma (TBPH) Cost of Revenue (2014 - 2018)

Theravance Biopharma (TBPH) has reported Cost of Revenue for 5 consecutive years, with $632000.0 the latest figure, recorded in Q4 2018.

• In Q4 2018, Cost of Revenue fell 72.52% year-over-year to $632000.0; the TTM figure through Dec 2018 stood at $3.6 million (down 30.74% YoY), while the FY2018 annual figure was $715000.0, down 88.14% from the prior year.
• Cost of Revenue declined to $632000.0 in Q4 2018 per TBPH's latest filing, from $705000.0 in the prior quarter.
• Across five years, Cost of Revenue topped out at $3.2 million in Q4 2014 and bottomed at $188000.0 in Q1 2014.
• Historically, Cost of Revenue has averaged $1.0 million across 5 years, with a median of $671500.0 in 2016.
• Annual changes were most pronounced in 2017 — Cost of Revenue surged 196.69% — and 2018, when it sank 72.52%.
• Theravance Biopharma's Cost of Revenue stood at $3.2 million in 2014, then decreased by 0.65% to $3.2 million in 2015, then tumbled by 64.2% to $1.1 million in 2016, then jumped by 100.7% to $2.3 million in 2017, then tumbled by 72.52% to $632000.0 in 2018.
• Business Quant data shows TBPH's Cost of Revenue at $632000.0 in Q4 2018, $705000.0 in Q3 2018, and $1.4 million in Q2 2018.